In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The C-Suite Speaks

The Eye Travels Wide: ProQR’s Bid For Leadership In The Genetics Of Sight

How did a youthful vendor of IT services, faced with a personal exposure to crippling illness, attract some of the best minds in biotech to launch a company with a then-untested RNA technology that today is a contender for leadership in the rarified space of inherited retinal disease? The answer may lie in the ambitiously definitive name that 36-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures.

C-Suite Speaks Gene Therapy Innovation

Building Bayer For The Next Decade And Navigating A Patent Cliff

As Bayer prepares for several of its key products to lose patent exclusivity in four to five years’ time, In Vivo caught up with the company’s new head of pharma, Stefan Oelrich, to hear more on his strategy for the future – especially his plans for drug R&D, collaboration and a pipeline built on external innovation.

C-Suite Speaks Leadership Strategy
Advertisement

Latest From C-Suite Speaks

Corporate Affairs: Biopharma’s First Line Of Defense Against Scrutiny

Amgen’s Judy Gawlik Brown is using her finance and consumer health background to make the big biotech’s message more authentic and accessible – a brisk reset against today’s disconnected world of alternative facts.

C-Suite Speaks Leadership

GSK's Hal Barron On R&D Progress At Two-Year Mark

Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

C-Suite Speaks Research and Development Strategies

PureTech’s Problem-Solving Skills Target The BIG Picture

PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.

C-Suite Speaks Business Strategies

C-Suite Snippets: Open Data And Innovation

In case you missed it: catch up with snippets from interviews published by In Vivo this month.

BioPharmaceutical Medical Device

MorphoSys: A European Champion Crossing The Biopharma Rubicon

The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.

BioPharmaceutical C-Suite Speaks

Going Back To The Future To Treat Diabetes

Applied Therapeutics has a business model that defies the conventional wisdom about start-up success: reviving science abandoned by big pharma; financing from a narrow group of investors, dependent on the goodwill of a single academic institution; all in pursuit of a small molecule solution to one of the biggest, diversely complex and cost-defying challenges in chronic disease – the complications of diabetes. 

C-Suite Speaks Innovation

Illumina CSO Bentley Paints A Vision For The Future Of Precision Medicine

Genomic medicine is coming of age. For Illumina chief scientific officer David Bentley, that not only means improved technology, accuracy and coverage of gene sequencing and a broadening into cancer, but also a better understanding among the wider population of disease and precisely the benefits that gene sequencing can bring to patients – actual and pre-symptomatic.

C-Suite Speaks Leadership

What Does It Take To Launch And Lead An Oncology Biotech Today?

Oncolytic virus company Theolytics has emerged ready to raise a series A round and get its preclinical assets into human trials by 2021. CEO Charlotte Casebourne talks to In Vivo about the challenge of standing out from the crowd in oncology, how viruses have evolved as a treatment approach in cancer, and how oncolytic viruses might be able to answer the cancer drug pricing conundrum.

Business Strategies C-Suite Speaks

Building The Biotech City: Is Los Angeles The Go-To Destination For Tomorrow’s Drug Innovations?

The complexity of producing viable drug candidates is increasing as an abundance of new science keeps extending the range of possible targets and fragmenting disease subtypes. Proximity to novel exploratory research is a driver of pipeline productivity – so can physical location within a communal geography of well-resourced intellectual firepower raise the odds for R&D success? In Vivo sits down with eight key leaders in academia, VC, commercial real estate and groundbreaking biotech to discuss how Los Angeles – the “out there” city of out-sized ambitions – is positioning itself for global leadership in the curative technologies of the future.

US States Growth

The Long Game In Dementia Diagnosis Can Be Laced With Short-Term Wins

IXICO has been developing medical image analysis and digital health data analytics to help pharma companies better understand how to develop so-far largely elusive therapies for neurological diseases. It is a game of skill, patience and long-term application, but also an environment with short-term opportunities, as IXICO’s Alison Howie explains.

Business Strategies Leadership

Reimagining IT: Bausch Health Puts Customers First In Planning For A Data-Driven Future

Information is the lifeblood that sustains drug development – but the ability to disperse, differentiate and make sense of it is what delivers success in the marketplace. Bausch Health Companies has decided to make global alignment through the strategic application of IT the centerpiece of its effort to shed the legacy of its acquisitive predecessor Valeant Pharmaceuticals. 

Business Strategies C-Suite Speaks

The Many Paths To Biotech CEO

There is no single path toward becoming a CEO. The job requires many different skills, often concurrently: sharp analytical capabilities, strategic thinking, clear communication with multiple audiences, curiosity and perseverance. It demands strong leadership but also humility, and a willingness to acknowledge mistakes and knowledge gaps.

C-Suite Speaks Business Strategies

Biotech CEOs: Can Scientist-Founders Remain In Charge?

Founder-CEOs do not typically remain at the helm as biotechs mature. Exceptions to that rule are multiplying, though, especially in Europe as companies aim directly for Nasdaq.

C-Suite Speaks Business Strategies

TISSIUM CEO’s Vision Is To Make The Tissue Recon Label Stick

Christophe Bancel, CEO of French medtech innovator TISSIUM, has made a career in various parts of the health care products industry, identifying business opportunities, founding, directing and leading ventures, and planning for contingencies. The ex-Serono and UCB executive, who has had many other postings, is now testing his adaptability and leadership qualities by bringing a versatile class III synthetic polymer device into key markets.

Business Strategies C-Suite Speaks

Growing And Innovating As A CDMO Business

Frank Mathias, CEO of Rentschler Biopharma, a contract development and manufacturing organization, talks to In Vivo about the company’s new corporate strategy and why he allowed 18 months to prepare that plan for delivery.

C-Suite Speaks Business Strategies
See All

Pharma’s New R&D Models: Federating Innovation

Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.

 
Market Intelligence Business Strategies BioPharmaceutical

ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.

BioPharmaceutical Deals ImmunoOncology

Inside Bayer Oncology: An Interview With Robert LaCaze

Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.

Business Strategies Deals BioPharmaceutical

Hack Attack: Biopharma Cyber Chiefs Fight Back

The threat of cyberattacks on biopharma’s extensive information assets is moving to the top of the list of business risks confronting senior C-suite management. In Vivo’s Roundtable panel of leading biopharma CISOs reviews what to do and what it will take to convince others in senior management to buy into a challenge that still remains largely below the surface.

BioPharmaceutical Leadership Risk Management

Admedus CEO Ready To Transform Company Again With TAVR

The ups, downs – and nearly outs – of ASX-listed health technologies manufacturer and distributor Admedus have made compelling reading in the past two years, but CEO Wayne Paterson has brought a competitive edge to a company that was lacking focus. Now he is looking to raise the bar again, aiming to use the company's proprietary Adapt patch technology in the TAVR space, while also pressing on with strategic plans for the therapeutic vaccines portfolio and adding scale.

Business Strategies Cardiovascular Growth

Fortress Biotech: A Drug Financing Experiment Expands

Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.

Business Strategies Financing Deals

With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Business Strategies Cancer BioPharmaceutical

Flex Health Outsources To A Medtech Industry In Flux

Flex Health Solutions' role in the medtech space is helping other companies develop superior products for the broadest market appeal. Its ability to source ideas for medical design from other parts of its $24 billion business means it is already leveraging the Fourth Industrial Revolution, just at the point that the industry is undergoing dramatic change.

Manufacturing Innovation Medical Device

Olympus Dives Back Into M&A With Image Stream Medical Buy

When Olympus Corp. re-entered the M&A arena after five years of "back to the basics," it was via the purchase of a company that meets every parameter of its requirements. Nacho Abia says that OR integrator Image Stream Medical should also help the Japanese multinational stay on course to meet value-based – and ambitious mid-term sales – targets.

Deals M & A Medical Device

Becton Dickinson Adds A Bigger Jewel To Its String Of Pearls

Becton Dickinson President, Chairman and CEO Vincent Forlenza speaks to IN VIVO about the business prospects at Becton Dickinson as it integrates its major acquisition, CareFusion, and oversees a major internal group restructuring, and about his role as the current chairman of AdvaMed.

Medical Device BioPharmaceutical Business Strategies

CRF Leaders Take A Long Look At Medtech

Cardiovascular Research Foundation leaders Jack Lewin, Juan Granada, and Ori Ben-Yehuda talk to IN VIVO about the state of medtech innovation and health care in the US.

Medical Device Innovation C-Suite Speaks

Mark Gelfand And Howard Levin, The Folks Who Brought You Renal Denervation

Renal denervation is arguably the hottest new device technology to come along in years, with applications in a variety of chronic diseases including hypertension and diabetes, to name just two. Yet just over a decade ago, most people laughed off the concept, and they might still be laughing were it not for the efforts of a novel device development company called Coridea.

Medical Device North America Strategy

Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada

In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.

BioPharmaceutical Research and Development Strategies Deals

The New Math Of Ortho Innovation – An Interview With Zimmer CEO David Dvorak

After emerging from the DOJ settlements, the leading pure-play orthopedics company is emphasizing – and redefining – innovation to drive growth. Zimmer CEO David Dvorak talks to IN VIVO about his company’s commitment to innovation, and how the very notion of innovation is changing.

Medical Device Business Strategies Innovation
UsernamePublicRestriction

Register

Advertisement